Bionano Genomics Stock Performance
| BNGO Stock | USD 3.53 0.10 2.92% |
The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bionano Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bionano Genomics is expected to be smaller as well. At this point, Bionano Genomics has a negative expected return of -0.21%. Please make sure to confirm Bionano Genomics' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Bionano Genomics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bionano Genomics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in August 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.75 | Five Day Return 1.16 | Year To Date Return (77.22) | Ten Year Return (94.33) | All Time Return (94.33) |
Last Split Factor 1:60 | Last Split Date 2025-01-27 |
1 | Disposition of 402 shares by Jonathan Dixon of Bionano Genomics at 1.27 subject to Rule 16b-3 | 05/08/2025 |
2 | Q1 2025 Bionano Genomics Inc Earnings Call Transcript | 05/15/2025 |
3 | Bionano Achieves Milestone with New CPT Code for Genetic Testing BNGO Stock News | 05/19/2025 |
4 | Bionano Genomics Receives Buy Rating and Price Target Upgrade BNGO Stock News | 05/20/2025 |
5 | Disposition of 3568 shares by Mark Oldakowski of Bionano Genomics at 0.48 subject to Rule 16b-3 | 05/27/2025 |
6 | Acquisition by Adamchak Mark of 3029 shares of Bionano Genomics at 3.47 subject to Rule 16b-3 | 05/30/2025 |
7 | Disposition of tradable shares by Jonathan Dixon of Bionano Genomics at 3.69 subject to Rule 16b-3 | 06/03/2025 |
8 | Bionano Genomics, Inc. Short Interest Update | 06/06/2025 |
9 | Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the ... | 06/18/2025 |
10 | What drives Bionano Genomics Inc. stock price - Free Stock Market Mentorship - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 18.3 M | |
| Total Cashflows From Investing Activities | 73.8 M |
Bionano Genomics Relative Risk vs. Return Landscape
If you would invest 410.00 in Bionano Genomics on April 23, 2025 and sell it today you would lose (57.00) from holding Bionano Genomics or give up 13.9% of portfolio value over 90 days. Bionano Genomics is currently does not generate positive expected returns and assumes 2.5254% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Bionano, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bionano Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bionano Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bionano Genomics, and traders can use it to determine the average amount a Bionano Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0829
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BNGO |
Estimated Market Risk
| 2.53 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bionano Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bionano Genomics by adding Bionano Genomics to a well-diversified portfolio.
Bionano Genomics Fundamentals Growth
Bionano Stock prices reflect investors' perceptions of the future prospects and financial health of Bionano Genomics, and Bionano Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionano Stock performance.
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.94) % | ||||
| Operating Margin | (1.31) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 3.36 M | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 0.24 X | ||||
| Price To Sales | 0.41 X | ||||
| Revenue | 30.78 M | ||||
| Gross Profit | 494 K | ||||
| EBITDA | (97.47 M) | ||||
| Net Income | (112.02 M) | ||||
| Cash And Equivalents | 187.34 M | ||||
| Cash Per Share | 0.65 X | ||||
| Total Debt | 27.3 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.75 X | ||||
| Book Value Per Share | 15.54 X | ||||
| Cash Flow From Operations | (68.92 M) | ||||
| Earnings Per Share | (53.53) X | ||||
| Market Capitalization | 11.74 M | ||||
| Total Asset | 76.67 M | ||||
| Retained Earnings | (693.23 M) | ||||
| Working Capital | 2.15 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 8.72 M | ||||
About Bionano Genomics Performance
By examining Bionano Genomics' fundamental ratios, stakeholders can obtain critical insights into Bionano Genomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bionano Genomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 133.54 | 177.18 | |
| Return On Tangible Assets | (1.67) | (1.76) | |
| Return On Capital Employed | (2.64) | (2.78) | |
| Return On Assets | (1.46) | (1.53) | |
| Return On Equity | (3.17) | (3.32) |
Things to note about Bionano Genomics performance evaluation
Checking the ongoing alerts about Bionano Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bionano Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bionano Genomics generated a negative expected return over the last 90 days | |
| Bionano Genomics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 30.78 M. Net Loss for the year was (112.02 M) with profit before overhead, payroll, taxes, and interest of 494 K. | |
| Bionano Genomics currently holds about 187.34 M in cash with (68.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65. | |
| Bionano Genomics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: What drives Bionano Genomics Inc. stock price - Free Stock Market Mentorship - Jammu Links News |
- Analyzing Bionano Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionano Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Bionano Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bionano Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionano Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bionano Genomics' stock. These opinions can provide insight into Bionano Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (53.53) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.